This invention provides the first-in-class targeted therapy for acute kidney injury (AKI) by systemically administering protein WFDC2.

UCSF researchers have developed a novel small molecule drug that specifically targets and inhibits SLC26A3 (DRA), an anion exchanger whose inhibition is expected to have therapeutic benefit in constipation and oxalate kidney stone disease.